Date
Feb 24, 2020

STALICLA SA, a near clinical stage Swiss Biotech company leading the field of precision medicine for Neurodevelopmental Disorders (NDDs) - including conditions like Autism Spectrum Disorder (ASD) or Developmental Delay - today announced the successful closure of the second tranche of its series A for an amount of USD 8M (CHF 7.7M).

The round was supported by a consortium of Swiss, European and US private equity and Biotech experienced investors. STALICLA will use the proceeds of this second tranche to move its lead ASD precision medicine candidate - STP1 - into Phase 1b clinical trials and its second program, STP2, into IND enabling pre-clinical studies. 
https://bwnews.pr/2HAxOAc

i-news-events